6th Jul 2015 07:36
LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said it has received positive results from its clinical study on Acarovac Plus for the treatment of house dust mite allergy.
The tolerability of the product was demonstrated in the year-long study, with no adverse effects observed, the company said. The nasal airways assessments showed a reduction in symptoms of more than 50% during follow-up visits after one year of using the product.
Immunological markers were also assessed and showed significant improvements in antibody IgG4 and anti-inflammatory IL-10 molecules, indicating tolerance induction in patients after one year of treatment, Allergy added.
"Following the continued successful development of the Pollinex Quattro product range addressing the seasonal segment of the allergy market, we now intend to extend this innovative franchise into developing perennial allergy vaccines," said Manuel Llobet, Allergy's chief executive.
Allergy Therapeutics shares were down 2.1% to 23.00 pence on Monday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.